WntResearch’s CEO to BioStock: “If the effect is confirmed, there are good opportunities for licensing agreements next year”

In the Q1 report, Per Norlén writes his first CEO statement for WntResearch since taking office in March. The company’s focus right now is on the NeoFox study where recruitment is in full swing.

– We will put most of our focus on patient recruitment and business development in the near future, says Per in a comment to BioStock.

Read the full article at biostock.se:

https://www.biostock.se/en/2024/05/wntresearchs-ceo-if-the-effect-is-confirmed-there-are-good-opportunities-for-licensing-agreements-next-year/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se